Gerald Martin

Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE.

Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality.